What Are Intellectual Property Rights?

Intellectual Property Rights (IPR) are legal rights granted to creators and inventors to protect their creations of the mind — inventions, literary and artistic works, designs, symbols, names, and images. IPR provides exclusive rights for a limited period, balancing the interests of creators (who need incentives to innovate) with the public interest (which benefits from the diffusion of knowledge).

Types of Intellectual Property

Type What It Protects Duration (India) Governing Law (India)
Patents Inventions — new, inventive, and industrially applicable products or processes 20 years from filing date Patents Act, 1970 (amended 2005)
Copyrights Literary, dramatic, musical, and artistic works; cinematograph films; sound recordings Lifetime of author + 60 years (for literary works); 60 years from publication (for films, sound recordings) Copyright Act, 1957
Trademarks Distinctive signs (words, logos, symbols, sounds) that distinguish goods/services 10 years, renewable indefinitely Trade Marks Act, 1999
Industrial designs Ornamental or aesthetic aspects of an article — shape, pattern, configuration, colour 10 years, extendable by 5 years (total 15 years) Designs Act, 2000
Geographical Indications (GI) Products originating from a specific geographical location with qualities attributable to that origin 10 years, renewable indefinitely Geographical Indications of Goods Act, 1999
Trade secrets Confidential business information — formulas, processes, customer lists No registration; protected as long as secrecy is maintained No specific legislation — protected under contract law, common law, and the Information Technology Act
Plant varieties New plant varieties developed through breeding 6–18 years depending on the type of plant Protection of Plant Varieties and Farmers' Rights Act, 2001
Semiconductor layout designs Layout designs of integrated circuits 10 years from filing Semiconductor Integrated Circuits Layout-Design Act, 2000

For Mains: IPR is fundamentally about balance — between incentivising innovation and ensuring public access to knowledge. In the Indian context, this balance is particularly important in pharmaceuticals (patent protection vs affordable medicines), agriculture (plant variety protection vs farmers' rights), and traditional knowledge (protecting indigenous knowledge from biopiracy).

Patents — The Central IPR in Science & Technology

Patents Act, 1970 — Key Features

Feature Detail
Enacted 1970; came into effect on 20 April 1972
Major amendment 2005 amendment — introduced product patents for all fields of technology (including pharmaceuticals and agrochemicals), bringing India into compliance with TRIPS
Pre-2005 regime Only process patents (not product patents) were granted for food, medicines, and chemicals — this enabled India's generic pharmaceutical industry to grow
Patent term 20 years from the date of filing
Patentability criteria Novelty + Inventive step (non-obvious) + Industrial applicability
Controller General The Controller General of Patents, Designs and Trademarks administers the patent system through patent offices in Kolkata (head office), Mumbai, Delhi, and Chennai

What Is NOT Patentable in India (Key Exclusions — Section 3)

Section Exclusion
3(b) Inventions whose use would be contrary to public order or morality, or which cause serious harm to human, animal, or plant life or the environment
3(c) Discovery of a scientific principle or formulation of an abstract theory
3(d) Mere discovery of a new form of a known substance unless it results in enhanced efficacy — the "anti-evergreening" provision
3(e) Substance obtained by a mere admixture resulting only in aggregation of properties
3(h) Method of agriculture or horticulture
3(i) Any process for the medicinal, surgical, curative, prophylactic, diagnostic, therapeutic or other treatment of human beings or animals
3(j) Plants and animals in whole or any part thereof (other than microorganisms); essentially biological processes for production or propagation of plants and animals
3(k) Mathematical or business methods, computer programmes per se, algorithms

Section 3(d) — The Anti-Evergreening Provision

This is India's most internationally significant patent provision. It prevents "evergreening" — the practice of making minor modifications to existing drugs (changing salt form, crystal structure, etc.) to extend patent protection beyond the original 20 years.

Full text of the key portion: The mere discovery of a new form of a known substance which does not result in the enhancement of the known efficacy of that substance, or the mere discovery of any new property or new use for a known substance, is not patentable.

Clarification: Salts, esters, ethers, polymorphs, metabolites, pure form, particle size, isomers, mixtures of isomers, complexes, combinations, and other derivatives of known substances shall be considered the same substance, unless they differ significantly in properties with regard to efficacy.

For Prelims: Section 3(d) of the Patents Act prevents evergreening. It was the central legal provision in the landmark Novartis vs Union of India case (2013). India does not grant patents for mathematical methods, business methods, or computer programmes per se.

Landmark Patent Cases in India

Novartis AG vs Union of India (2013) — The Glivec Case

Aspect Detail
Drug Glivec (Gleevec) — imatinib mesylate, a cancer drug used for chronic myeloid leukaemia (CML)
Novartis' claim Patent for the beta-crystalline form of imatinib mesylate — Novartis argued this was a new and improved form of the drug
India's rejection Madras Patent Office (2006) rejected the application under Section 3(d) — the new form did not show enhanced therapeutic efficacy
Supreme Court judgment 1 April 2013 — the Court unanimously upheld the rejection, ruling that "efficacy" in Section 3(d) means therapeutic efficacy for pharmaceutical substances, not mere physical properties (solubility, stability, bioavailability)
Key quote Physical properties like stability, solubility, and hygroscopicity may be advantageous but they do not directly make the drug better at curing disease
Impact on drug pricing After the ruling, generic versions of imatinib were available at approximately USD 88 per month, compared to Novartis' price of approximately USD 2,200 per month
Global significance The case established India as a defender of affordable medicines and validated the use of TRIPS flexibilities by developing countries

Natco Pharma vs Bayer Corporation (2012) — India's First Compulsory Licence

Aspect Detail
Drug Sorafenib tosylate (brand name Nexavar) — used for liver and kidney cancer
Patent holder Bayer Corporation
Applicant Natco Pharma Ltd
Decision 12 March 2012 — the Controller General of Patents granted India's first (and so far only) compulsory licence under Section 84(1) of the Patents Act
Three grounds (Section 84) (1) Reasonable requirements of the public not satisfied; (2) Drug not available at reasonably affordable price — Bayer charged Rs 2.8 lakh for a month's supply; (3) Patented invention not worked (manufactured) in India
Terms Natco allowed to sell Nexavar at Rs 8,800 per month (compared to Bayer's Rs 2,80,000); Natco to pay Bayer a 6% royalty on net sales
Upheld Appellate Board (IPAB) upheld the decision in 2013; Bayer's appeal dismissed

For Mains: The Nexavar compulsory licence case demonstrates the use of TRIPS flexibilities to ensure access to affordable medicines. Section 84 of the Patents Act allows compulsory licensing on three grounds — unmet public need, unaffordable pricing, and non-working of the patent in India. Critics argue that compulsory licensing discourages pharmaceutical R&D investment in India; supporters argue it is essential to prevent patent monopolies from pricing out life-saving treatments.

TRIPS Agreement

Overview

Feature Detail
Full name Agreement on Trade-Related Aspects of Intellectual Property Rights
Adopted 1994 as part of the Uruguay Round of GATT negotiations; came into effect on 1 January 1995 with the establishment of the WTO
Administered by World Trade Organization (WTO)
Significance The first comprehensive multilateral agreement on intellectual property — sets minimum standards for IP protection that all WTO members must comply with
India's compliance India amended the Patents Act in 2005 to introduce product patents for pharmaceuticals — the key requirement for TRIPS compliance

Key Provisions of TRIPS

Provision Description
Minimum standards All WTO members must provide minimum levels of IP protection for patents (20 years), copyrights (50 years after death), trademarks, GIs, industrial designs, etc.
National treatment Each WTO member must give nationals of other WTO members treatment no less favourable than its own nationals
Most Favoured Nation (MFN) Any advantage, favour, privilege or immunity granted to nationals of one country must be extended to nationals of all WTO members
Enforcement Members must provide effective enforcement mechanisms — judicial and administrative procedures, border measures, criminal sanctions
Dispute settlement IP disputes between WTO members can be brought before the WTO Dispute Settlement Body

TRIPS Flexibilities

Flexibility Description
Compulsory licensing Members can issue compulsory licences allowing production of patented products without the patent holder's consent, subject to certain conditions (Article 31)
Parallel imports Members can import patented products from any country where they are sold at a lower price
Government use Governments can use patented inventions for public, non-commercial purposes
Transition periods Developing countries were given transition periods to comply (India used the full period until 2005)
Section 3(d) type provisions TRIPS does not prohibit higher patentability standards than the minimum — India's Section 3(d) is TRIPS-compliant

The Doha Declaration on TRIPS and Public Health (2001)

Feature Detail
Adopted 14 November 2001, at the WTO Ministerial Conference in Doha, Qatar
Core statement "The TRIPS Agreement does not and should not prevent members from taking measures to protect public health"
Key affirmations Members have the right to grant compulsory licences; each member has the right to determine what constitutes a national emergency; the right to establish exhaustion regimes (parallel imports) without challenge
Paragraph 6 solution Addressed the problem of countries with insufficient manufacturing capacity — led to the TRIPS amendment (Article 31bis, effective 2017) allowing export of generics under compulsory licence to countries that cannot manufacture them
Significance Reaffirmed the primacy of public health over patent protection and legitimised the use of TRIPS flexibilities by developing countries

For Prelims: The Doha Declaration (2001) reaffirmed the right of WTO members to use TRIPS flexibilities (compulsory licensing, parallel imports) for public health. Article 31bis (effective 2017) was the amendment to TRIPS allowing export of generic drugs under compulsory licence to countries without manufacturing capacity.

Geographical Indications (GI Tags)

GI Framework in India

Feature Detail
Governing law Geographical Indications of Goods (Registration and Protection) Act, 1999
Came into effect 15 September 2003
Registrar Geographical Indications Registry, Chennai
Duration 10 years, renewable indefinitely
First GI tag in India Darjeeling Tea (2004-05) — from West Bengal
Total GI tags registered 658 as of early 2026
Categories Agriculture (Basmati rice, Alphonso mango), handicrafts (Pashmina, Kancheepuram silk), foodstuffs (Ratlami sev, Hyderabadi Haleem), manufactured goods (Mysore Agarbatti), natural goods (Makrana marble)

Notable GI-Tagged Products

Product State Significance
Darjeeling Tea West Bengal First GI tag in India; internationally protected — the word mark and logo are recognised globally
Basmati Rice Multiple states (Punjab, Haryana, UP, Uttarakhand, HP, J&K, Delhi) Contested GI — Pakistan also claims Basmati; India has sought GI protection in the EU
Pashmina Jammu & Kashmir Premium textile; GI protection helps distinguish genuine Pashmina from machine-made imitations
Mysore Silk Karnataka Protected against misuse of the "Mysore Silk" name
Tirupati Laddu Andhra Pradesh One of India's most distinctive food products with GI protection
Madhubani Paintings Bihar Traditional art form with GI protection
Kancheepuram Silk Tamil Nadu High-value silk textile with centuries of heritage

GI Tags vs Patents vs Trademarks

Feature GI Tag Patent Trademark
Protects Origin-linked quality and reputation Inventions Brand identity
Ownership Community/collective (producers in the region) Individual/company Individual/company
Duration 10 years, renewable indefinitely 20 years (non-renewable) 10 years, renewable indefinitely
Territorial Tied to a specific geographical area Territorial (country where filed) Territorial but can be extended
Can be sold/transferred No — cannot be bought, sold, or licensed Yes — can be assigned, licensed Yes — can be assigned, licensed

For Prelims: India has 658 registered GI tags as of early 2026. The first GI tag was Darjeeling Tea (2004-05). GI tags are registered at the Geographical Indications Registry in Chennai. Unlike patents, GI tags are community-owned and cannot be sold or transferred.

Traditional Knowledge Protection

The Biopiracy Problem

Biopiracy refers to the appropriation of traditional knowledge, genetic resources, or biological materials by external parties (typically corporations or researchers from developed countries) through the patent system, without authorisation from or compensation to the communities that developed and preserved that knowledge.

Landmark Biopiracy Cases Involving India

Case Year Details
Turmeric patent 1995–1997 Two scientists at the University of Mississippi obtained a US patent for wound-healing properties of turmeric. India's CSIR challenged the patent, presenting prior art from ancient Sanskrit texts. The US Patent and Trademark Office (USPTO) revoked the patent in 1997 — a landmark victory
Neem patent 1994–2005 The European Patent Office (EPO) granted W.R. Grace & Co. a patent for a neem-based antifungal product. After a decade-long legal battle, the EPO revoked the patent in 2005, accepting that the use was part of traditional knowledge
Basmati rice 1997 RiceTec Inc. (US) obtained a patent for "Basmati rice lines and grains." India challenged several claims, and the USPTO narrowed the patent significantly — removing claims on the name "Basmati"

Traditional Knowledge Digital Library (TKDL)

Feature Detail
Established 2001 — collaboration between CSIR and the then Ministry of Health and Family Welfare
Purpose Prevent the granting of wrong patents based on traditional knowledge by making India's traditional knowledge available to patent examiners worldwide in a format and language they can use
Content Documentation of over 4.5 lakh formulations from traditional Indian medicine systems — Ayurveda, Unani, Siddha, Yoga
Languages Translated into 5 international languages (English, French, German, Spanish, Japanese) using a specially developed Traditional Knowledge Resource Classification (TKRC)
Access agreements TKDL has signed agreements with major patent offices — EPO, USPTO, UKPTO, and others — granting access for prior art searches
Impact Led to the withdrawal or rejection of over 300 patent applications worldwide that attempted to claim traditional Indian knowledge as novel

For Mains: India's TKDL is a defensive protection mechanism — it prevents others from patenting India's traditional knowledge, but it does not generate economic returns for traditional knowledge holders. India needs complementary "positive protection" — legal mechanisms that enable traditional knowledge holders to commercially exploit their knowledge and receive benefits. The Biological Diversity Act, 2002 provides for benefit-sharing but enforcement has been weak.

National Intellectual Property Rights Policy, 2016

Feature Detail
Approved 12 May 2016 by the Union Cabinet
Nodal department Department for Promotion of Industry and Internal Trade (DPIIT), Ministry of Commerce and Industry
Objectives Creative India; Innovative India — foster innovation and creativity across all sectors
Key pillars (1) IP awareness and outreach, (2) Generation of IPRs, (3) Legal and legislative framework, (4) IP administration and management, (5) Commercialisation of IP, (6) Enforcement and adjudication, (7) Human capital development
Cell for IPR Promotion and Management (CIPAM) Established under DPIIT to implement the policy; conducts IP awareness programmes, handles anti-piracy activities
IP Facilitation Centre Provides free facilitation services for startups under the Startup India programme

India's Patent Filing Performance

Metric Data
Global ranking India became the world's 6th largest patent filer in 2024 (WIPO Intellectual Property Indicators 2025)
Total filings in 2024 Over 63,000 patent applications
Resident share For the first time, over 55% of India's patent applications were filed by domestic applicants (2023) — previously, foreign applicants dominated
Growth trend Eighth consecutive year of growth; 16.5% increase in 2024; third consecutive year of double-digit growth
Top 10 across all categories For the first time, India ranked in the top 10 globally across patents, trademarks, and industrial designs

For Prelims: India's National IPR Policy was approved in 2016. India became the 6th largest patent filer globally in 2024 (WIPO report). Over 55% of India's patent applications are now from domestic applicants — a significant shift from the previous dominance of foreign filers.

Plant Variety Protection and Farmers' Rights

Protection of Plant Varieties and Farmers' Rights Act, 2001

Feature Detail
Enacted 2001; Protection of Plant Varieties and Farmers' Rights Authority (PPVFRA) established in 2005
Purpose Provides IP protection for plant varieties developed through breeding while protecting the rights of farmers
Types of registration New variety, Extant variety, Essentially derived variety, Farmers' variety
Duration 15 years for crops (18 years for trees and vines) from date of registration
Farmers' rights (Section 39) Farmers can save, use, sow, re-sow, exchange, share, and sell farm produce including seed of a protected variety — but cannot sell branded seed
Benefit sharing Breeders must share benefits with farming communities that contributed to the development of genetic resources
Unique feature India's PVPFRA is unique globally because it includes farmers' rights alongside breeders' rights — unlike UPOV (International Union for the Protection of New Varieties of Plants) which focuses solely on breeders' rights

For Mains: India's PVPFRA (2001) is a sui generis (unique) system as permitted under TRIPS Article 27.3(b). It balances breeders' rights with farmers' rights — a critically important balance in a country where agriculture is the primary livelihood for hundreds of millions. India chose not to join UPOV precisely because UPOV restricts farmers' rights to save and exchange seeds.

Copyright in the Digital Age

Key Challenges

Challenge Detail
Digital piracy Unauthorised copying and distribution of copyrighted content (movies, music, software, books) has been vastly amplified by the internet
Fair use vs piracy The boundary between legitimate fair use (research, criticism, education) and piracy is increasingly blurred in the digital context
AI-generated content Who owns the copyright on content created by AI? Can AI be an "author" under copyright law? Current Indian law requires a human author
Open access The movement towards open access to scientific research (particularly publicly funded research) challenges traditional journal publishing models
DRM and access Digital Rights Management (DRM) technologies can restrict legitimate uses (e.g., a visually impaired person using text-to-speech on an e-book)
Platform liability Should platforms (YouTube, social media) be liable for copyrighted content uploaded by users? India's IT Act and Copyright Act create a "safe harbour" with conditions

India's Copyright Act, 1957 (Key Features)

Feature Detail
Scope Protects literary, dramatic, musical, and artistic works; cinematograph films; sound recordings
Duration Author's lifetime + 60 years for literary, dramatic, musical, and artistic works
Fair dealing Section 52 provides a list of acts that do not constitute infringement — private use, research, criticism, review, reporting current events, education
Copyright Board Previously, Copyright Board handled disputes; now transferred to the Appellate Board/Commercial Courts
Marrakesh Treaty India ratified the Marrakesh Treaty (2014) which facilitates access to published works for persons who are blind, visually impaired, or otherwise print-disabled

Evergreening and Data Exclusivity

Evergreening

Aspect Detail
Definition Strategy used by pharmaceutical companies to extend patent protection beyond 20 years by obtaining new patents on minor modifications of existing drugs — new formulations, dosage forms, salt forms, combinations
How it works When the original patent on a blockbuster drug is about to expire, the company files patents on modifications, effectively blocking generic competition
India's response Section 3(d) of the Patents Act specifically targets evergreening — it prevents patenting of new forms unless enhanced therapeutic efficacy is demonstrated
Global debate Pharmaceutical companies argue modifications genuinely improve drugs; critics argue it is a strategy to maintain monopoly pricing

Data Exclusivity

Aspect Detail
Definition A period during which regulatory authorities cannot rely on the originator's clinical trial data to approve generic versions — even if the patent has expired or no patent exists
Current Indian position India does NOT provide data exclusivity — generic manufacturers can rely on the originator's data for regulatory approval (bioequivalence studies are sufficient)
Pressure on India US and EU have pushed India to adopt data exclusivity through bilateral trade agreements; the US Special 301 Report has placed India on the "Priority Watch List"
Impact if adopted Data exclusivity would delay generic entry even for drugs not protected by patents — increasing medicine prices significantly
India's defence Data exclusivity is not required by TRIPS; adopting it would undermine India's generic pharmaceutical industry and increase medicine prices for developing countries

For Mains: Data exclusivity is distinct from patent protection. Even when a drug has no patent (or the patent has been invalidated under Section 3(d)), data exclusivity would prevent generic competition for several years. India's refusal to grant data exclusivity is as important as Section 3(d) in maintaining affordable medicine access. The US has consistently pressured India on this issue through the Special 301 Report and bilateral negotiations.

Key Terms for Quick Revision

Term Meaning
TRIPS Trade-Related Aspects of Intellectual Property Rights — WTO agreement setting minimum IP standards
Section 3(d) Anti-evergreening provision of India's Patents Act — prevents patenting of new forms unless enhanced therapeutic efficacy is shown
Compulsory licensing Government-authorised production of a patented product without the patent holder's consent (Section 84, Patents Act)
GI tag Geographical Indication — protects products with qualities attributable to their geographical origin
TKDL Traditional Knowledge Digital Library — defensive database preventing biopiracy of India's traditional knowledge
Doha Declaration 2001 WTO declaration affirming that TRIPS should not prevent measures to protect public health
Evergreening Strategy to extend patent monopoly through minor modifications — prevented by Section 3(d)
Data exclusivity Period during which regulators cannot use originator's clinical trial data for generic approval — India does NOT provide this
PVPFRA Protection of Plant Varieties and Farmers' Rights Act, 2001 — protects both breeders' and farmers' rights
Biopiracy Appropriation of traditional knowledge or biological resources without consent or benefit-sharing
CIPAM Cell for IPR Promotion and Management — implements National IPR Policy under DPIIT
Article 31bis TRIPS amendment (effective 2017) allowing export of generics under compulsory licence to countries without manufacturing capacity

Exam Strategy

For Mains Answer Writing: IPR questions in GS-III often focus on the tension between innovation incentives and public access. The Novartis case, Nexavar compulsory licence, biopiracy cases, and India's pharmaceutical industry are your go-to examples. Always frame answers around India's position — use of TRIPS flexibilities, Section 3(d), refusal of data exclusivity — and explain why these positions serve both national interest and global public health. For GI tags, discuss their role in protecting rural livelihoods and traditional products, but also note challenges (weak enforcement, low awareness among artisans, limited commercial exploitation).

For Prelims: Key facts — Patents Act 1970 (amended 2005), patent term 20 years, Section 3(d) (anti-evergreening), Novartis case (2013), Nexavar compulsory licence (2012), TRIPS effective 1995, Doha Declaration 2001, first GI tag Darjeeling Tea (2004-05), 658 GI tags (2026), TKDL established 2001, National IPR Policy 2016, India 6th largest patent filer (2024), PVPFRA 2001.